AGA technical review on osteoporosis in gastrointestinal diseases

Gastroenterology

Volumn 124, Issue 3, 2003, Pages 795-841

  Bernstein, Charles N ^a,c   Leslie, William D ^a   Leboff, Meryl S ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c American Gastroenterological Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CONJUGATED ESTROGEN; ESTROGEN DERIVATIVE; FLUORIDE SODIUM; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

BONE BIOPSY; BONE DENSITY; BONE METABOLISM; CELIAC DISEASE; DENSITOMETRY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; ENTERITIS; EVIDENCE BASED MEDICINE; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; MEDICAL LITERATURE; MEDICAL SOCIETY; MORPHOMETRICS; OSTEOMALACIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTGASTRECTOMY SYNDROME; PREVALENCE; PRIORITY JOURNAL; REVIEW; VITAMIN D METABOLISM;

EID: 0037370124     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2003.50106     Document Type: Review

References (299)

1. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999;159:1215-1220.
2. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-882.
3. von der RP, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999;106:273-278.
4. Leslie W, Bernstein CN, LeBoff MS. AGA review on osteoporosis and hepatic disorders. Gastroenterology 2003;124:791-794.
5. Sackett DHR, Guyatt G, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. 2nd ed. Boston: Little, Brown, 1991.
6. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000;31:1005-1013.
7. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305-311.
8. Martin TJ, Ng KW, Suda T. Bone cell physiology. Endocrinol Metab Clin North Am 1989;18:833-858.
9. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000;108:153-164.
10. Heaney RP, Abrams S, Dawson-Hughes B, Looker A, Marcus R, Matkovic V, Weaver C. Peak bone mass. Osteoporos Int 2000;11:985-1009.
11. Stewart TL, Ralston SH. Role of genetic factors in the pathogenesis of osteoporosis. J Endocrinol 2000;166:235-245.
12. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129.
13. Smith CB, Smith DA. Relations between age, mineral density and mechanical properties of human femoral compacta. Acta Orthop Scand 1976;47:496-502.
14. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337-349.
15. Vleggaar FP, van Buuren HR, Wolfhagen FHJ, Schalm SW, Pols HAP. Prevention and treatment of osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:617-621.
16. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology ad hoc Committee on Glucocoritcoid-Induced Osteoporosis. Arthritis Rheum 2001;44:1496-1503.
17. Sambrook PN, Eisman JA, Yeates MG, Pocock NA, Eberl S, Champion GD. Osteoporosis in rheumatoid arthritis: safety of low-dose corticosteroids. Ann Rheum Dis 1986;45:950-953.
18. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993;34:1543-1546.
19. Haddad JG Jr, Hahn TJ. Natural and synthetic sources of circulating 25-hydroxyvitamin D in man. Nature 1973;244:515-516.
20. Preece MA, Tomlinson S, Ribot CA, Pietrek J, Korn HT, Davies DM, Ford JA, Dunnigan MG, O'Riordan JL. Studies of vitamin D deficiency in man. Q J Med 1975;44:575-589.
21. Basha B, Rao DS, Han ZH, Parfitt AM. Osteomalacia due to vitamin D depletion: a neglected consequence of intestinal malabsorption. Am J Med 2000;108:296-300.
22. Raisz LG. Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med 1988;318:818-828.
23. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309.
24. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, Woitge H, Seibel MJ, Ziegler R, Pfeilschifter J. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001;86:2032-2042.
25. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916.
26. Aubin JE, Bonnelye E. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 2000;11:905-913.
27. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development. Immunol Cell Biol 1999;77:188-193.
28. Kong YY, Penninger JM. Molecular control of bone remodeling and osteoporosis. Exp Gerontol 2000;35:947-956.
29. Fuleihan GE, Testa MA, Angell JE, Porrino N, LeBoff MS. Reproducibility of DXA absorptiometry: a model for bone loss estimates. J Bone Miner Res 1995;10:1004-1014.
30. Smith CB, Smith DA. Relations between age, mineral density and mechanical properties of human femoral compacta. Acta Orthop Scand 1976;47:496-502.
31. Courtney AC, Wachtel EF, Myers ER, Hayes WC. Age-related reductions in the strength of the femur tested in a fall-loading configuration. J Bone Joint Surg Am 1995;77:387-395.
32. Miller PD, Zapalowski C, Kulak CA, Bilezikian JP. Bone densitometry: the best way to detect osteoporosis and to monitor therapy. J Clin Endocrinol Metab 1999;84:1867-1871.
33. Madden AM, Morgan MY. The potential role of dual-energy X-ray absorptiometry in the assessment of body composition in cirrhotic patients. Nutrition 1997;13:40-45.
34. Santolaria F, Gonzalez-Reimers E, Perez-Manzano JL, Milena A, Gomez-Rodriguez M, Gonzalez-Diaz A, de la Vega MJ, Martinez-Riera A. Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients. Alcohol 2000;22:147-157.
35. Gluer CC. Quantitative ultrasound techniques for the assessment of osteoporosis: expert agreement on current status. The International Quantitative Ultrasound Consensus Group. J Bone Miner Res 1997;12:1280-1288.
36. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-323.
37. Svendsen OL, Hassager C, Skodt V, Christiansen C. Impact of soft tissue on in vivo accuracy of bone mineral measurements in the spine, hip, and forearm: a human cadaver study. J Bone Miner Res 1995;10:868-873.
38. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Toner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541.
39. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993;341:72-75.
40. Lenchik L, Watts NB. Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis. J Clin Densitom 2001;4:1-4.
41. LeBoff MS, Fuleihan GE, Angell JE, Chung S, Curtis K. Dual-energy X-ray absorptiometry of the forearm: reproducibility and correlation with single-photon absorptiometry. J Bone Miner Res 1992;7:841-846.
42. Pocock NA, Sambrook PN, Nguyen T, Kelly P, Freund J, Eisman JA. Assessment of spinal and femoral bone density by dual X-ray absorptiometry: comparison of lunar and hologic instruments. J Bone Miner Res 1992;7:1081-1084.
43. De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998;13:1587-1593.
44. Floreani A, Fries W, Luisetto G, Burra P, Fagiuoli S, Boccagni P, Della Rovere GR, Plebani M, Piccoli A, Naccarato R. Bone metabolism in orthotopic liver transplantation: a prospective study. Liver Transpl Surg 1998;4:311-319.
45. Meys E, Fontanges E, Fourcade N, Thomasson A, Pouyet M, Delmas PD. Bone loss after orthotopic liver transplantation. Am J Med 1994;97:445-450.
46. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC, Jr, Lindsay RL. Proximal femur bone mineral levels of US adults. Osteoporos Int 1995;5:389-409.
47. Faulkner KG, von Stetten E, Miller P. Discordance in patient classification using T-scores. J Clin Densitom 1999;2:343-350.
48. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000;11:192-202.
49. Looker AC, Bauer DC, Chesnut CH, III, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000;11:467-480.
50. Bauer DC, Sklarin PM, Stone KL, Black DM, Nevitt MC, Ensrud KE, Arnaud CD, Genant HK, Garnero P, Delmas PD, Lawaetz H, Cummings SR. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 1999;14:1404-1410.
51. Melton LI III, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083-1091.
52. Chesnut CH III, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC Jr, Notelovitz M, Rosen C, Cain DF, Flessland KA, Mallinak NJ. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37.
53. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998;13:1431-1438.
54. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000;85:3537-3540.
55. Miller PD, Baran DT, Bilezikian JP, Greenspan SL, Lindsay R, Riggs BL, Watts NB. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom 1999;2:323-342.
56. Eriksen EF, Steiniche T, Mosekilde L, Melsen F. Histomorphometric analysis of bone in metabolic bone disease. Endocrinol Metab Clin North Am 1989;18:919-954.
57. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987;2:595-610.
58. Compston JE, Chadha S, Merrett AL. Osteomalacia developing during treatment of osteoporosis with sodium fluoride and vitamin D. BMJ 1980;281:910-911.
59. Bolotin HH, Sievanen H, Grashuis JL, Kuiper JW, Jarvinen TL. Inaccuracies inherent in patient-specific dual-energy X-ray absorptiometry bone mineral density measurements: comprehensive phantom-based evaluation. J Bone Miner Res 2001;16:417-426.
60. Haderslev KV, Svendsen OL, Staun M. Does paracentesis of ascites influence measurements of bone mineral or body composition by dual-energy X-ray absorptiometry? Metabolism 1999;48:373-377.
61. Moller S, Hansen M, Hillingso J, Jensen JEB, Henriksen JH. Elevated carboxy terminal cross-linked telopeptide of type I collagen in alcoholic cirrhosis: relation to liver and kidney function and bone metabolism. Gut 1999;44:417-423.
62. Guanabens N, Pares A, Alvarez L, Martinez de Osaba MJ, Monegal A, Peris P, Ballesta AM, Rodes J. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 1998;13:731-738.
63. Pereira SP, Bray GP, Pitt PI, Li FM, Moniz C, Williams R. Noninvasive assessment of bone density in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:323-328.
64. Bonkovsky HL, Hawkins M, Steinberg K, Hersh T, Galambos JT, Henderson JM, Millikan WJ, Galloway JR. Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 1990;12:273-280.
65. Bagur A, Mautalen C, Findor J, Sorda J, Somoza J. Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis. Calcif Tissue Int 1998;63:385-390.
66. Knapen MH, Hamulyak K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med 1989;111:1001-1005.
67. Aksnes L, Aarskog D. Plasma concentrations of vitamin D metabolites in puberty: effect of sexual maturation and implications for growth. J Clin Endocrinol Metab 1982;55:94-101.
68. Seidman E, LeLeiko N, Ament M, Berman W, Caplan D, Evans J, Kocoshis S, Lake A, Motil K, Sutphen J. Nutritional issues in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991;12:424-438.
69. Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993;16:373-380.
70. Sabatier JP, Guaydier-Souquieres G, Benmalek A, Marcelli C. Evolution of lumbar bone mineral content during adolescence and adulthood: a longitudinal study in 395 healthy females 10-24 years of age and 206 premenopausal women. Osteoporos Int 1999;9:476-482.
71. Bertelloni S, Baroncelli GI, Ferdeghini M, Perri G, Saggese G. Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty. J Clin Endocrinol Metab 1998;83:4280-4283.
72. Seeman E, Karlsson MK, Duan Y. On exposure to anorexia nervosa, the temporal variation in axial and appendicular skeletal development predisposes to site-specific deficits in bone size and density: a cross-sectional study. J Bone Miner Res 2000;15:2259-2265.
73. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-1259.
74. Hans D, Dargent-Molina P, Schott AM, Sebert JL, Cormier C, Kotzki PO, Delmas PD, Pouilles JM, Breart G, Meunier PJ. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 1996;348:511-514.
75. Bauer DC, Gluer CC, Cauley JA, Vogt TM, Ensrud KE, Genant HK, Black DM. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1997;157:629-634.
76. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:767-773.
77. Genant HK, Mall JC, Wagonfeld JB, Horst JV, Lanzi LH. Skeletal demineralization and growth retardation in inflammatory bowel disease. Invest Radiol 1976;11:541-549.
78. Vogelsang H, Schofl R, Tillinger W, Ferenci P, Gangl A. 25-hydroxy-vitamin D absorption in patients with Crohn's disease and with pancreatic insufficiency. Wien Klin Wochenschr 1997;109:678-682.
79. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J. Osteoporosis in patients with inflammatory bowel disease. Gut 1987;28:410-415.
80. Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997;32:1247-1255.
81. Silvennoinen J. Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease. J Intern Med 1996;239:131-137.
82. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995;108:417-422.
83. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995;10:250-256.
84. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-923.
85. Lin CL, Moniz C, Chambers TJ, Chow JW. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996;111:1263-1271.
86. Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr 1997;24:289-295.
87. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998;93:1483-1490.
88. Compston JE, Ayers AB, Horton LW, Tighe JR, Creamer B. Osteomalacia after small-intestinal resection. Lancet 1978;1:9-12.
89. Vogelsang H, Ferenci P, Woloszczuk W, Resch H, Herold C, Frotz S, Gangl A. Bone disease in vitamin D-deficient patients with Crohn's disease. Dig Dis Sci 1989;34:1094-1099.
90. Hessov I, Mosekilde L, Melsen F, Fasth S, Hulten L, Lund B, Sorensen OH. Osteopenia with normal vitamin D metabolites after small-bowel resection for Crohn's disease. Scand J Gastroenterol 1984;19:691-696.
91. Croucher PI, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporos Int 1993;3:236-241.
92. Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997;112:1710-1713.
93. Boot AM, Bouquet J, Krenning EP, Muinck Keizer-Schrama SM. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 1998;42:188-194.
94. Semeao EJ, Jawad AF, Zemel BS, Neiswender KM, Piccoli DA, Stallings VA. Bone mineral density in children and young adults with Crohn's disease. Inflamm Bowel Dis 1999;5:161-166.
95. Herzog D, Bishop N, Glorieux F, Seidman EG. Interpretation of bone mineral density values in pediatric Crohn's disease. Inflamm Bowel Dis 1998;4:261-267.
96. Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998;114:902-911.
97. Cowan FJ, Gregory JW, Jenkins HR. Bone mineral density in Crohn's disease. Gut 1997;41:578-579.
98. Semeao EJ, Jawad AF, Stouffer NO, Zemel BS, Piccoli DA, Stallings VA. Risk factors for low bone mineral density in children and young adults with Crohn's disease. J Pediatr 1999;135:593-600.
99. Issenman RM, Atkinson SA, Radoja C, Fraher L. Longitudinal assessment of growth, mineral metabolism, and bone mass in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 1993;17:401-406.
100. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy MT, Montbrun T, Listrat V, Dougados M, Couturier D, Amor B. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992;37:1396-1403.
101. Roux C, Abitbol V, Chaussade S, Kolta S, Guillemant S, Dougados M, Amor B, Couturier D. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995;5:156-160.
102. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228-233.
103. Robinson RJ, Al Azzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K, Mayberry JF. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998;43:2500-2506.
104. Schoon EJ, van Nunen AB, Wouters RSME, Stockbrugger RW, Russel MGVM. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol 2000;35:43-47.
105. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995;37:71-76.
106. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997;40:313-319.
107. Robinson RJ, Al Azzawi F, Iqbal SJ, Abrams K, Mayberry JF. The relation of hand skin-fold thickness to bone mineral density in patients with Crohn's disease. Eur J Gastroenterol Hepatol 1997;9:945-949.
108. Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998;4:268-275.
109. Staun M, Tjellesen L, Thale M, Schaadt O, Jarnum S. Bone mineral content in patients with Crohn's disease: a longitudinal study in patients with bowel resections. Scand J Gastroenterol 1997;32:226-232.
110. Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol 2000;95:699-704.
111. Ghosh S, Cowen S, Hannah WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994;107:1031-1039.
112. Lee SH, Kim HJ, Yang SK, Kim WH, Joo YS, Dong SH, Kim BH, Lee JI, Chang YW, Chang R. Decreased trabecular bone mineral density in newly diagnosed inflammatory bowel disease patients in Korea. J Gastroenterol Hepatol 2000;15:512-518.
113. Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJM. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000;119:1203-1208.
114. Clements D, Motley RJ, Evans WD, Harries AD, Rhodes J, Coles RJ, Compston JE. Longitudinal study of cortical bone loss in patients with inflammatory bowel disease. Scand J Gastroenterol 1992;27:1055-1060.
115. Bischoff SC, Herrmann A, Goke M, Manns MP, von Zur MA, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997;92:1157-1163.
116. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol 1999;94:824-828.
117. Ulivieri FM, Lisciandrano D, Ranzi T, Taioli E, Cermesoni L, Piodi LP, Nava MC, Vezzoli M, Bianchi PA. Bone mineral density and body composition in patients with ulcerative colitis. Am J Gastroenterol 2000;95:1491-1494.
118. Dinca M, Fries W, Luisetto G, Peccolo F, Bottega F, Leone L, Naccarato R, Martin A. Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol 1999;94:1292-1297.
119. Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Porro GB. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000;247:63-70.
120. Silvennoinen J, Lamberg-Allardt C, Karkkainen M, Niemela S, Lehtola J. Dietary calcium intake and its relation to bone mineral density in patients with inflammatory bowel disease. J Intern Med 1996;240:285-292.
121. Teichmann J, Lange U, Stracke H, Doppl W, Klor HU, Federlin K. Rapid spinal trabecular bone loss in female patients with ileitis terminalis Crohn and additional sacroiliac joint inflammation. Rheumatol Int 1997;17:45-48.
122. Robinson RJ, Iqbal SJ, Abrams K, Al Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther 1998;12:699-705.
123. Fries W, Dinca M, Luisetto G, Peccolo F, Bottega F, Martin A. Calcaneal ultrasound bone densitometry in inflammatory bowel disease: a comparison with double X-ray densitometry of the lumbar spine. Am J Gastroenterol 1998;93:2339-2344.
124. Robinson RJ, Carr I, Iqbal SJ, Al Azzawi F, Abrams K, Mayberry JF. Screening for osteoporosis in Crohn's disease: a detailed evaluation of calcaneal ultrasound. Eur J Gastroenterol Hepatol 1998;10:137-140.
125. Rannem T, Hylander E, Jamum S, Ladefoged K, Schaadt O, Staun M, Thale M. Calcium absorption and bone mineral content in patients subjected to ileal bypass because of familial hypercholesterolaemia. Scand J Gastroenterol 1990;25:897-905.
126. Floren CH, Ahren B, Bengtsson M, Bartosik J, Obrant K. Bone mineral density in patients with Crohn's disease during long-term treatment with azathioprine. J Intern Med 1998;243:123-126.
127. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Ultrasound measurements of calcaneus for estimation of skeletal status in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:790-797.
128. Robinson RJ, Carr I, Iqbal SJ, Al Azzawi F, Abrams K, Mayberry JF. Screening for osteoporosis in Crohn's disease: a detailed evaluation of calcaneal ultrasound. Eur J Gastroenterol Hepatol 1998;10:137-140.
129. Motley RJ, Clements D, Evans WD, Crawley EO, Evans C, Rhodes J, Compston JF. A four-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993;23:95-104.
130. Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996;10:777-786.
131. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol 1999;34:696-702.
132. Abitbol V, Roux C, Guillemant S, Valleur P, Hautefeuille P, Dougados M, Couturier D, Chaussade S. Bone assessment in patients with ileal pouch-anal anastomosis for inflammatory bowel disease. Br J Surg 1997;84:1551-1554.
133. Staun M, Jarnum S. Measurement of the 10,000-molecular weight calcium-binding protein in small-intestinal biopsy specimens from patients with malabsorption syndromes. Scand J Gastroenterol 1988;23:827-832.
134. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000;46:176-181.
135. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002;156:1-10.
136. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med 2000;133:795-799.
137. Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LI III. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002;123:468-475.
138. Ciclitira PJ. American Gastroenterological Association technical review on celiac sprue. Gastroenterology 2001;120:1526-1540.
139. Delco F, El Serag HB, Sonnenberg A. Celiac sprue among US military veterans: associated disorders and clinical manifestations. Dig Dis Sci 1999;44:966-972.
140. Vasquez H, Mazure R, Gonzalez D, Flores D, Pedreira S, Niveloni S, Smecuol E, Maurino E, Bai JC. Risk of fractures in celiac disease patients: a cross-sectional, case-control study. Am J Gastroenterol 2000;95:183-189.
141. Fornari MC, Pedreira S, Niveloni S, Gonzalez D, Diez RA, Vazquez H, Mazure R, Sugai E, Smecuol E, Boerr L, Maurino E, Bai JC. Pre-and post-treatment serum levels of cytokines IL-1 beta, IL-6, and IL-1 receptor antagonist in celiac disease: are they related to the associated osteopenia? Am J Gastroenterol 1998;93:413-418.
142. Valdimarsson T, Arnqvist HJ, Toss G, Jarnerot G, Nystrom F, Strom M. Low circulating insulin-like growth factor I in coeliac disease and its relation to bone mineral density. Scand J Gastroenterol 1999;34:904-908.
143. Jameson S. Coeliac disease, insulin-like growth factor, bone mineral density, and zinc. Scand J Gastroenterol 2000;35:894-896.
144. Devine A, Rosen C, Mohan S, Baylink D, Prince RL. Effects of zinc and other nutritional factors on insulin-like growth factor I and insulin-like growth factor-binding proteins in postmenopausal women. Am J Clin Nutr 1998;68:200-206.
145. Wood RJ, Zheng JJ. High dietary calcium intakes reduce zinc absorption and balance in humans. Am J Clin Nutr 1997;65:1803-1809.
146. Kemppainen T, Kroger H, Janatuinen E, Arnala I, Kosma VM, Pikkarainen P, Julkunen R, Jurvelin J, Alhava E, Uusitupa M. Osteoporosis in adult patients with celiac disease. Bone 1999;24:249-255.
147. Selby PL, Davies M, Adams JE, Mawer EB. Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 1999;14:652-657.
148. Corazza GR, Di Stefano M, Jorizzo RA, Cecchetti L, Minguzzi L, Gasbarrini G. Propeptide of type I procollagen is predictive of posttreatment bone mass gain in adult celiac disease. Gastroenterology 1997;113:67-71.
149. Corazza GR, Di Sario A, Cecchetti L, Jorizzo RA, Di Stefano M, Minguzzi L, Brusco G, Bernardi M, Gasbarrini G. Influence of pattern of clinical presentation and of gluten-free diet on bone mass and metabolism in adult coeliac disease. Bone 1996;18:525-530.
150. Keaveny AP, Freaney R, McKenna MJ, Masterson J, O'Donoghue DP. Bone remodeling indices and secondary hyperparathyroidism in celiac disease. Am J Gastroenterol 1996;91:1226-1231.
151. Valdimarsson T, Lofman O, Toss G, Strom M. Reversal of osteopenia with diet in adult coeliac disease. Gut 1996;38:322-327.
152. Corazza GR, Di Sario A, Cecchetti L, Tarozzi C, Corrao G, Bernardi M, Gasbarrini G. Bone mass and metabolism in patients with celiac disease. Gastroenterology 1995;109:122-128.
153. Caraceni MP, Molteni N, Bardella MT, Ortolani S, Nogara A, Bianchi PA. Bone and mineral metabolism in adult celiac disease. Am J Gastroenterol 1988;83:274-277.
154. Fickling WE, McFarlane XA, Bhalla AK, Robertson DAF. The clinical impact of metabolic bone disease in coeliac disease. Postgrad Med J 2001;77:33-36.
155. Haden ST, Fuleihan GE, Angell JE, Cotran NM, LeBoff MS. Calcidiol and PTH levels in women attending an osteoporosis program. Calcif Tissue Int 1999;64:275-279.
156. Vogelsang H, Suk EK, Janisiw M, Stain C, Mayr WR, Panzer S. Calcaneal ultrasound attenuation and vitamin-D-receptor genotypes in celiac disease. Scand J Gastroenterol 2000;35:172-176.
157. Farthing MJ, Rees LH, Dawson AM. Male gonadal function in coeliac disease III: pituitary regulation. Clin Endocrinol (Oxf) 1983;19:661-671.
158. Sher KS, Jayanthi V, Probert CS, Stewart CR, Mayberry JF. Infertility, obstetric and gynecological problems in coeliac sprue. Dig Dis 1994;12:186-190.
159. Mora S, Barera G, Ricotti A, Weber G, Bianchi C, Chiumello G. Reversal of low bone density with a gluten-free diet in children and adolescents with celiac disease. Am J Clin Nutr 1998;67:477-481.
160. Mora S, Weber G, Barera G, Bellini A, Pasolini D, Prinster C, Bianchi C, Chiumello G. Effect of gluten-free diet on bone mineral content in growing patients with celiac disease. Am J Clin Nutr 1993;57:224-228.
161. Rea F, Polito C, Marotta A, Di Toro A, Iovene A, Collini R, Rea L, Sessa G. Restoration of body composition in celiac children after one year of gluten-free diet. J Pediatr Gastroenterol Nutr 1996;23:408-412.
162. Barera G, Mora S, Brambilla P, Ricotti A, Menni L, Beccio S, Bianchi C. Body composition in children with celiac disease and the effects of a gluten-free diet: a prospective case-control study. Am J Clin Nutr 2000;72:71-75.
163. Scotta MS, Salvatore S, Salvatoni A, De Amici M, Ghiringhelli D, Broggini M, Nespoli L. Bone mineralization and body composition in young patients with celiac disease. Am J Gastroenterol 1997;92:1331-1334.
164. Mustalahti K, Collin P, Sievanen H, Salmi J, Maki M. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 1999;354:744-745.
165. Gonzalez D, Mazure R, Mautalen C, Vazquez H, Bai J. Body composition and bone mineral density in untreated and treated patients with celiac disease. Bone 1995;16:231-234.
166. Di Stefano M, Veneto G, Corrao G, Corazza GR. Role of lifestyle factors in the pathogenesis of osteopenia in adult coeliac disease: a multivariate analysis. Eur J Gastroenterol Hepatol 2000;12:1195-1199.
167. Mautalen C, Gonzalez D, Mazure R, Vazquez H, Lorenzetti MP, Maurino E, Niveloni S, Pedreira S, Smecuol E, Boerr LA, Bai JC. Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients. Am J Gastroenterol 1997;92:313-318.
168. Ciacci C, Maurelli L, Klain M, Savino G, Salvatore M, Mazzacca G, Cirillo M. Effects of dietary treatment on bone mineral density in adults
169. Di Stefano M, Jorizzo RA, Veneto G, Cecchetti L, Gasbarrini G, Corazza GR. Bone mass and metabolism in dermatitis herpetiformis. Dig Dis Sci 1999;44:2139-2143.
170. Bai JC, Gonzalez D, Mautalen C, Mazure R, Pedreira S, Vazquez H, Smecuol E, Siccardi A, Cataldi M, Niveloni S, Boerr LA, Maurino E. Long-term effect of gluten restriction on bone mineral density of patients with coeliac disease. Aliment Pharmacol Ther 1997;11:157-164.
171. Sategna-Guidetti C, Grosso SB, Grosso S, Mengozzi G, Aimo G, Zaccaria T, Di Stefano M, Isaia GC. The effects of 1-year gluten withdrawal on bone mass, bone metabolism and nutritional status in newly-diagnosed adult coeliac disease patients. Aliment Pharmacol Ther 2000;14:35-43.
172. Valdimarsson T, Toss G, Lofman O, Strom M. Three years' follow-up of bone density in adult coeliac disease: significance of secondary hyperparathyroidism. Scand J Gastroenterol 2000;35:274-280.
173. Walters JR, Banks LM, Butcher GP, Fowler CR. Detection of low bone mineral density by dual energy X-ray absorptiometry in unsuspected suboptimally treated coeliac disease. Gut 1995;37:220-224.
174. Molteni N, Caraceni MP, Bardella MT, Ortolani S, Gandolini GG, Bianchi P. Bone mineral density in adult celiac patients and the effect of gluten-free diet from childhood. Am J Gastroenterol 1990;85:51-53.
175. McFarlane XA, Bhalla AK, Reeves DE, Morgan LM, Robertson DA. Osteoporosis in treated adult coeliac disease. Gut 1995;36:710-714.
176. Bode S, Hassager C, Gudmand-Hoyer E, Christiansen C. Body composition and calcium metabolism in adult treated coeliac disease. Gut 1991;32:1342-1345.
177. Pistorius LR, Sweidan WH, Purdie DW, Steel SA, Howey S, Bennett JR, Sutton D. Coeliac disease and bone mineral density in adult female patients. Gut 1995;37:639-642.
178. Cellier C, Flobert C, Cormier C, Roux C, Schmitz J. Severe osteopenia in symptom-free adults with a childhood diagnosis of coeliac disease. Lancet 2000;355:806-806.
179. Valdimarsson T, Toss G, Ross I, Lofman O, Strom M. Bone mineral density in coeliac disease. Scand J Gastroenterol 1994;29:457-461.
180. Meyer D, Stavropolous S, Diamond B, Shane E, Green PHR. Osteoporosis in a North American adult population with celiac disease. Am J Gastroenterol 2001;96:112-119.
181. Kemppainen T, Kroger H, Janatuinen E, Arnala I, Lamberg-Allardt C, Karkkainen M, Kosma VM, Julkunen R, Jurvelin J, Alhava E, Uusitupa M. Bone recovery after a gluten-free diet: A 5-year follow-up study. Bone 1999;25:355-360.
182. Feighery C. Osteoporosis and coeliac disease: reply (letter). BMJ 2000;320:715.
183. McFarlane XA, Bhalla AK, Robertson DA. Effect of a gluten-free diet on osteopenia in adults with newly diagnosed coeliac disease. Gut 1996;39:180-184.
184. Molteni N, Bardella MT, Vezzoli G, Pozzoli E, Bianchi P. Intestinal calcium absorption as shown by stable strontium test in celiac disease before and after gluten-free diet. Am J Gastroenterol 1995;90:2025-2028.
185. Cook HB, Burt MJ, Collett JA, Whitehead MR, Frampton CM, Chapman BA. Adult coeliac disease: prevalence and clinical significance. J Gastroenterol Hepatol 2000;15:1032-1036.
186. Sonnenberg A. Peptic ulcer. In: Everhart J, ed. Digestive disease in the United States: epidemiology and impact. Washington, DC: US Government Printing Office, 1994:359-408.
187. Thompson GR. Vitamin D deficiency after gastrectomy. Sci Basis Med Annu Rev 1970;:260-275.
188. Filipponi P, Gregorio F, Cristallini S, Mannarelli C, Blass A, Scarponi AM, Vespasiani G. Partial gastrectomy and mineral metabolism: effects on gastrin-calcitonin release. Bone Miner 1990;11:199-208.
189. Nilas L, Christiansen C. Influence of PTH and 1,25(OH)2D on calcium homeostasis and bone mineral content after gastric surgery. Calcif Tissue Int 1985;37:461-466.
190. Resch H, Pietschmann P, Pernecker B, Krexner E, Willvonseder R. The influence of partial gastrectomy on biochemical parameters of bone metabolism and bone density. Clin Invest 1992;70:426-429.
191. Kwon SJ, Hahm JS, Cho YJ, Ahn Y, Shin DI. The influence of gastrectomy on the change of bone metabolism and bone density. Korean J Intern Med 2000;15:25-31.
192. Klein KB, Orwoll ES, Lieberman DA, Meier DE, McClung MR, Parfitt AM. Metabolic bone disease in asymptomatic men after partial gastrectomy with Billroth II anastomosis. Gastroenterology 1987;92:608-616.
193. Schmiedl A, Schwille PO, Stuhler C, Gohl J, Rumenapf G. Low bone mineral density after total gastrectomy in males: a preliminary report emphasizing the possible significance of urinary net acid excretion, serum gastrin and phosphorus. Clin Chem Lab Med 1999;37:739-744.
194. Inoue K, Shiomi K, Higashide S, Kan N, Nio Y, Tobe T, Shigeno C, Konishi J, Okumura H, Yamamuro T. Metabolic bone disease following gastrectomy: assessment by dual energy X-ray absorptiometry. Br J Surg 1992;79:321-324.
195. Mellstrom D, Rundgren A. Long-term effects after partial gastrectomy in elderly men: a longitudinal population study of men between 70 and 75 years of age. Scand J Gastroenterol 1982;17:433-439.
196. Wetscher G, Redmond E, Watfah C, Perdikis G, Gadenstatter M, Pointner R. Bone disorders following total gastrectomy. Dig Dis Sci 1994;39:2511-2515.
197. Mellstrom D, Johansson C, Johnell O, Lindstedt G, Lundberg PA, Obrant K, Schoon IM, Toss G, Ytterberg BO. Osteoporosis, metabolic aberrations, and increased risk for vertebral fractures after partial gastrectomy. Calcif Tissue Int 1993;53:370-377.
198. Blichert-Toft M, Beck A, Christiansen C, Transbol I. Effects of gastric resection and vagotomy on blood and bone mineral content. World J Surg 1979;3:99-105.
199. Hirano Y, Kishimoto H, Hagino H, Teshima R. The change of bone mineral density in secondary osteoporosis and vertebral fracture incidence. J Bone Miner Metab 1999;17:119-124.
200. Thompson GR, Lewis B, Booth CC. Vitamin D absorption after partial gastrectomy. Lancet 1966;1:457-458.
201. Kanis J, Johnell O, Gullberg B, Allander E, Elffors L, Ranstam J, Dequeker J, Dilsen G, Gennari C, Vaz AL, Lyritis G, Mazzuoli G, Miravet L, Passeri M, Perez Cano R, Rapado A, Ribot C. Risk factors for hip fracture in men from southern Europe: the Mediterranean osteoporosis study. Osteoporos Int 1999;9:45-54.
202. Tovey FI, Godfrey JE, Lewin MR. A gastrectomy population: 25-30 years on. Postgrad Med J 1990;66:450-456.
203. Orwoll ES, Bevan L, Phipps KR. Determinants of bone mineral density in older men. Osteoporos Int 2000;11:815-821.
204. Imamura M, Yamauchi H, Fukushima K, Sasaki I, Ouchi A. Bone metabolism following gastric surgery: microdensitometry and single-photon absorptiometry. Tohoku J Exp Med 1988;156:237-249.
205. Hoikka V, Alhava EM, Savolainen K, Karjalainen P, Parviainen M. The effect of partial gastrectomy on bone mineral metabolism. Scand J Gastroenterol 1982;17:257-261.
206. Liedman B, Bosaeus I, Mellstrom D, Lundell L. Osteoporosis after total gastrectomy: results of a prospective, clinical study. Scand J Gastroenterol 1997;32:1090-1095.
207. Paakkonen M, Alhava EM, Karjalainen P. Bone mineral and intestinal calcium absorption after partial gastrectomy. Scand J Gastroenterol 1982;17:369-372.
208. Tougaard L, Rickers H, Rodbro P, Thaysen EH, Christensen MS, Lund B, Sorensen O. Bone composition and vitamin D after Polya gastrectomy. Acta Med Scand 1977;202:47-50.
209. Bisballe S, Eriksen EF, Melsen F, Mosekilde L, Sorensen OH, Hessov I. Osteopenia and osteomalacia after gastrectomy: interrelations between biochemical markers of bone remodeling, vitamin D metabolites, and bone histomorphometry. Gut 1991;32:1303-1307.
210. Krogsgaard MR, Frolich A, Lund B. Long-term changes in bone mass after partial gastrectomy in a well-defined population and its relation to tobacco and alcohol consumption. World J Surg 1995;19:867-871.
211. Eddy RL. Metabolic bone disease after gastrectomy. Am J Med 1971;50:442-449.
212. Gertner JM, Lilburn M, Domenech M. 25-hydroxycholecalciferol absorption in steatorrhoea and postgastrectomy osteomalacia. BMJ 1977;1:1310-1312.
213. Davies M, Heys SE, Selby PL, Berry JL, Mawer EB. Increased catabolism of 25-hydroxyvitamin D in patients with partial gastrectomy and elevated 1,25-dihydroxyvitamin D levels: implications for metabolic bone disease. J Clin Endocrinol Metab 1997;82:209-212.
214. Tovey FI, Hall ML, Ell PJ, Hobsley M. A review of postgastrectomy bone disease. J Gastroenterol Hepatol 1992;7:639-645.
215. Hakanson R, Persson P, Axelson J, Johnell O, Sundler F. Evidence that gastrin enhances 45Ca uptake into bone through release of a gastric hormone. Regul Pept 1990;28:107-118.
216. Rumenapf G, Schwille PO, Erben RG, Schreiber M, Berge B, Fries W, Schmiedl A, Koroma S, Hohenberger W. Gastric fundectomy in the rat: effects on mineral and bone metabolism, with emphasis on the gastrin-calcitonin-parathyroid hormone-vitamin D axis. Calcif Tissue Int 1998;63:433-441.
217. Fries W, Rumenapf G, Schwille PO. Disturbances of mineral and bone metabolism following gastric antrectomy in the rat. Bone Miner 1992;19:245-256.
218. Recker RR. Calcium absorption and achlorhydria. N Engl J Med 1985;313:70-73.
219. Adachi Y, Shiota E, Matsumata T, Iso Y, Yoh R, Kitano S. Bone mineral density in patients taking H2-receptor antagonist. Calcif Tissue Int 1998;62:283-285.
220. Marcinowska-Suchowierska EB, Talalaj MJ, Wlodarcyzk AW, Bielecki K, Zawadzki JJ, Brzozowski R. Calcium/phosphate/vitamin D homeostasis and bone mass in patients after gastrectomy, vagotomy, and cholecystectomy. World J Surg 1995;19:597-601.
221. Stenstrom M, Olander B, Lehto-Axtelius D, Madsen JE, Nordsletten L, Carlsson GA. Bone mineral density and bone structure parameters as predictors of bone strength: an analysis using computerized microtomography and gastrectomy-induced osteopenia in the rat. J Biomech 2000;33:289-297.
222. Bordier P, Matrajt H, Hioco D, Hepner GW, Thompson GR, Booth CC. Subclinical vitamin D deficiency following gastric surgery: histological evidence in bone. Lancet 1968;1:437-440.
223. Garrick R, Ireland AW, Posen S. Bone abnormalities after gastric surgery: a prospective histological study. Ann Intern Med 1971;75:221-225.
224. Tovey FI, Karamanolis DG, Godfrey J, Clark CG. Screening for early post-gastrectomy osteomalacia. Practitioner 1987;231:817-822.
225. Tovey FI, Karamanolis DG, Godfrey J, Clark CG. Post-gastrectomy nutrition: methods of outpatient screening for early osteomalacia. Hum Nutr Clin Nutr 1985;39:439-446.
226. Morgan DB, Paterson CR, Woods CG, Pulvertaft CN, Fourman P. Osteomalacia after gastrectomy: a response to very small doses of vitamin D. Lancet 1965;2:1089-1091.
227. Peach H, Compston JE, Vedi S, Horton LW. Value of plasma calcium, phosphate, and alkaline phosphatase measurements in the diagnosis of histological osteomalacia. J Clin Pathol 1982;35:625-630.
228. Adachi Y, Shiota E, Matsumata T, Iso Y, Yoh R, Kitano S. Osteoporosis after gastrectomy: bone mineral density of lumbar spine assessed by dual-energy X-ray absorptiometry. Calcif Tissue Int 2000;66:119-122.
229. Heiskanen JT, Kroger H, Paakkonen M, Parviainen MT, Lamberg-Allardt C, Alhava E. Bone mineral metabolism after total gastrectomy. Bone 2001;28:123-127.
230. Zittel TT, Zeeb B, Maier GW, Kaiser GW, Zwirner M, Liebich H, Starlinger M, Becker HD. High prevalence of bone disorders after gastrectomy. Am J Surg 1997;174:431-438.
231. Nishimura O, Furumoto T, Nosaka K, Kouno K, Sumikawa M, Hisaki T. Bone disorder following partial and total gastrectomy with reference to bone mineral content. Jpn J Surg 1986;16:98-105.
232. Aukee S, Alhava EM, Karjalainen P. Bone mineral after partial gastrectomy II. Scand J Gastroenterol 1975;10:165-169.
233. Alhava EM, Aukee S, Karjalainen P. Bone mineral after partial gastrectomy I. Scand J Gastroenterol 1974;9:463-466.
234. a. Nihei Z, Kojima K, Ichikawa W, Hirayama R, Mishima Y. Chronological changes in bone mineral content following gastrectomy. Surg Today 1996;26:95-100.
235. b. Melton LI III, Crowson CS, Khosla S, O'Fallon WM. Fracture risk after surgery for peptic ulcer disease: a population based cohort study. Bone 1999;25:61-67.
236. Nilsson BE, Westlin NE. The fracture incidence after gastrectomy. Acta Chir Scand 1971;137:533-534.
237. Arnaud SB. 25-hydroxyvitamin D3 treatment of bone disease in primary biliary cirrhosis. Gastroenterology 1982;83:137-140.
238. NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994;272:1942-1948.
239. Adams JS, Song CF, Kantorovich V. Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide. Ann Intern Med 1999;130:658-660.
240. Ray WA, Griffin MR, Downey W, Melton LI III. Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1989;1:687-690.
241. Delaney M, LeBoff MS. Metabolic bone disease. In: Ruddy S, Harris ED Jr, Sledge CB, eds. Textbook of rheumatology, 6th ed. Philadelphia: Saunders, 1999:1635-1652.
242. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999;281:1505-1511.
243. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-676.
244. Capuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-1642.
245. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol: a randomized controlled study. Ann Intern Med 1990;113:649-655.
246. Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357-362.
247. Brown JP, Burckhardt P, Reid IR, Horowitz ZD, Richardson PC, Treschsel U. Zoledronic acid, at a total annual dose of 4 mg, increases bone density at all sites and stably reduces bone turnover for one year when administered as a single or a 3-monthly intravenous injection in postmenopausal osteoporosis (abstract). Am Soc Bone Miner Density [F353] 2001;S218.
248. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988;241:84-86.
249. Manolagas SC, Jilka RL. Cytokines, hematopoiesis, osteoclastogenesis, and estrogens. Calcif Tissue Int 1992;50:199-202.
250. Pacifici R, Rifas L, McCracken R, Vered I, McMurtry C, Avioli LV, Peck WA. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Natl Acad Sci U S A 1989;86:2398-2402.
251. Pacifici R. Is there a causal role for IL-1 in postmenopausal bone loss? Calcif Tissue Int 1992;50:295-299.
252. Roussow JE, Anderson GL, Prencie RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
253. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-2197.
254. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
255. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, Leboff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF study group. Am J Med 2000;109:267-276.
256. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 1995;333:1437-1443.
257. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 1999;282:1344-1352.
258. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-340.
259. Delaney MF, Shaw J, Hurwitz S, LeBoff MS. Effect of one weekly risedronate on bone density in postmenopausal osteoporosis (abstr). Am Soc Bone Miner Density 2001;SA360.
260. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC III, Yanover MJ. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-79.
261. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, Loeb G, Rouillon A, Barry S, Evreux JC, Avouac B, Marchandise X. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO Study. Osteoporos Int 1998;8:4-12.
262. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ, III. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990;322:802-809.
263. Slovik DM, Rosenthal DI, Doppelt SH, Potts JT Jr, Daly MA, Campbell JA, Neer RM. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D. J Bone Miner Res 1986;1:377-381.
264. Roe EB, Sanchez SD, Del Puerto GA. Treatment of postmenopausal osteoporosis with human parathyroid hormone 1-34 and estrogen (abstract). Endocr Soc Meet 1999;S631:59.
265. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441.
266. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1063-1069.
267. Hahn TJ. Steroid- and drug-induced osteopenia. In: Kleerekoper M, ed. Primer of the metabolic diseases and disorders of mineral metabolism. 2nd ed. Am Soc Bone Miner Res 1993:250-255.
268. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961-968.
269. Dykman TR, Haralson KM, Gluck OS, Murphy WA, Teitelbaum SL, Hahn TJ, Hahn BH. Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984;27:1336-1343.
270. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993;328:1747-1752.
271. Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia: effect of 25-hydroxyvitamin D administration. J Clin Invest 1979;64:655-665.
272. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996;156:1173-1177.
273. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG, Jr, Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-1972.
274. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-364.
275. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994;37:1499-1505.
276. Sambrook P, Birmingham J, Champion D, Kelly P, Kempler S, Freund J, Eisman J. Postmenopausal bone loss in rheumatoid arthritis: effect of estrogens and androgens. J Rheumatol 1992;19:357-361.
277. Adachi JD, Bensen WG, Bell MJ, Bianchi FA, Cividino AA, Craig GL, Sturtridge WC, Sebaldt RJ, Steele M, Gordon M, Themeles E, Tugwell P, Roberts R, Gent M. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997;36:255-259.
278. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1988;1:143-146.
279. Adachi JD. Corticosteroid-induced osteoporosis. Am J Med Sci 1997;313:41-49.
280. Roux C, Adachi JD, Cooper C, Moniz C, Dequeker J, Ioannidis G, Cawley MI, Jenkins EA, Walker-Bone KE, Pack S, Stephenson GS, Laan RF, Brown J, Gevsens P. Pooled results from three randomized trials on the prevention of corticosteroid-induced osteoporosis with etiodronate (abstract). Bone 1998;23:W460.
281. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med 1998;339:292-299.
282. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European corticosteroid-induced osteoporosis treatment study. J Bone Miner Res 2000;15:1006-1013.
283. Guaydier-Souquieres G, Kotzki PO, Sabatier JP, Basse-Cathalinat B, Loeb G. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study. Osteoporos Int 1996;6:171-177.
284. Rickers H, Deding A, Christiansen C, Rodbro P, Naestoft J. Corticosteroid-induced osteopenia and vitamin D metabolism: effect of vitamin D2, calcium phosphate and sodium fluoride administration. Clin Endocrinol (Oxf) 1982;16:409-415.
285. Meunier PJ, Briancon D, Chavassieu P. Treatment with fluoride: bone histomorphometric findings. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis. Viborg, Denmark: Norhaven AG, 1987:824.
286. Lane NE, Jenkins DK, Arnaud CD. Short-term increases in formation markers predict subsequent spine bone mineral density gains in women with glucocorticoid-induced osteoporosis treated with parathyroid hormone (abstract). Bone 1998;23:S159.
287. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995;7:609-614.
288. Vogelsang H, Klamert M, Resch H, Ferenci P. Dietary vitamin D intake in patients with Crohn's disease. Wien Klin Wochenschr 1995;107:578-581.
289. Von Tirpitz C, Klaus J, Bruckel J, Rieber A, Scholer A, Adler G, Bohm BO, Reinshagen M. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000;12:19-24.
290. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976;55:401-412.
291. Robinson RJ, Krzywicki T, Almond L, Al Azzawi F, Abrams K, Iqbal SJ, Mayberry JF. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology 1998;115:36-41.
292. Loudon CP, Corroll V, Butcher J, Rawsthorne P, Bernstein CN. The effects of physical exercise on patients with Crohn's disease. Am J Gastroenterol 1999;94:697-703.
293. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000;119:639-646.
294. Morgan DB, Paterson CR, Woods CG, Pulvertaft CN, Fourman P. Search for osteomalacia in 1228 patients after gastrectomy and other operations on the stomach. Lancet 1965;2:1085-1088.
295. Isaia G, Di Stefano M, Roggia C, Ardissone P, Rosina F. Bone disorders in cholestatic liver diseases. Forum (Genova) 1998;8:28-38.
296. Cowan FJ, Warner JT, Dunstan FD, Evans WD, Gregory JW, Jenkins HR. Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child 1997;76:325-329.
297. Scharla SH, Minne HW, Lempert UG, Leidig G, Hauber M, Raedsch R, Ziegler R. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). Exp Clin Endocrinol 1994;102:44-49.
298. Mora S, Barera G, Beccio S, Proverbio MC, Weber C, Bianchi C, Chiumello G. Bone density and bone metabolism are normal after long-term gluten-free diet in young celiac patients. Am J Gastroenterol 1999;94:398-403.
299. Mazure R, Vazquez H, Gonzalez D, Mautalen C, Pedreira S, Boerr L, Bai JC. Bone mineral affection in asymptomatic adult patients with celiac disease. Am J Gastroenterol 1994;89:2130-2134.